The first study to investigate the effects of IDA on HbA1C levels was by Horton, who demonstrated the mean HbA1C concentration for four patients with IDA as 4.9% compared with a mean HbA1C concentration of 5.3% among 14 healthy people.
Increasing evidence suggests a potential role of iron (Fe) in the pathogenesis of type 2 diabetes mellitus. Fe is a strong pro oxidant leading to reactive oxygen species (ROS) formation resulting in elevated oxidative stress. In animal models, Fe excess might result in pancreatic oxidative stress and decrease insulin secretary capacity. Ferritin is a marker of Fe status in healthy individuals and an acute phase reactant as well; elevated levels of ferritin have been shown in diabetic patients. This HbA1c enhancing effect of iron deficiency and fall in HbA1c levels after iron supplementation has been previously documented in several studies [17, 18].
Our results demonstrate that there is a relation between iron therapy and HbA1C in patients with type 2 DM. Our results are in accordance with the findings of Brooks et al. and Davis et al.’s study [19, 20]. They revealed a relationship between iron deficiency anemia and HbA1C levels and attempted to ex¬plain the alteration in HbA1C levels in iron deficiency anemia on the basis of both modifications to the structure of hemoglobin and levels of HbA1C in old and new red blood cells.
Koga et al. in association study of erythrocyte indices with glycated hemoglobin in pre-menopausal women